{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:36:18Z","timestamp":1791920178203,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejim.2023.05.012","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T08:22:38Z","timestamp":1683879758000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Tirzepatide and potential use for metabolically healthy obesity"],"prefix":"10.1016","volume":"113","author":[{"given":"Sidar","family":"Copur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Tanriover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furkan","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10113","key":"10.1016\/j.ejim.2023.05.012_bib0001","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.05.012_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.804719","article-title":"Advances in phenotyping obesity and in its dietary and pharmacological treatment: a narrative review","volume":"9","author":"Pujia","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.ejim.2023.05.012_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-48382-5_1","article-title":"The definition and prevalence of obesity and metabolic syndrome","volume":"960","author":"Engin","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.012_bib0004","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2012.113905","article-title":"Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis","volume":"309","author":"Flegal","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ejim.2023.05.012_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2213-8587(22)00073-0","article-title":"The actual burden of obesity-accounting for multimorbidity","volume":"10","author":"Tsur","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ejim.2023.05.012_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/metabo10020048","article-title":"Metabolically healthy obesity-heterogeneity in definitions and unconventional factors","volume":"10","author":"Brandao","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.ejim.2023.05.012_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2023.02.025","article-title":"Metabolically healthy obesity: misleading phrase or healthy phenotype?","author":"Tanriover","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"10","key":"10.1016\/j.ejim.2023.05.012_bib0008","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/obr.12198","article-title":"The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used","volume":"15","author":"Rey-Lopez","year":"2014","journal-title":"Obes Rev"},{"key":"10.1016\/j.ejim.2023.05.012_bib0009","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2147\/DMSO.S294894","article-title":"Metabolomic signature between metabolically healthy overweight\/obese and metabolically unhealthy overweight\/obese: a systematic review","volume":"14","author":"Cheng","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.ejim.2023.05.012_bib0010","article-title":"The risk for chronic kidney disease in metabolically healthy obese patients: a systematic review and meta-analysis","author":"Kanbay","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejim.2023.05.012_bib0011","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6823-14-9","article-title":"The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies","volume":"14","author":"van Vliet-Ostaptchouk","year":"2014","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.012_bib0012","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/ajcn\/nqz133","article-title":"Metabolically healthy obesity: what's in a name?","volume":"110","author":"Magkos","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ejim.2023.05.012_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.archger.2019.01.004","article-title":"Metabolically healthy obese phenotype and risk of cardiovascular disease: results from the China health and retirement longitudinal study","volume":"82","author":"Li","year":"2019","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.ejim.2023.05.012_bib0014","article-title":"Cardiovascular disease outcomes in metabolically healthy obesity in communities of Beijing cohort study","author":"Li","year":"2018","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.012_bib0015","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1210\/jc.2016-3346","article-title":"Metabolically healthy obesity and ischemic heart disease: a 10-year follow-up of the inter99 study","volume":"102","author":"Hansen","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ejim.2023.05.012_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003351","article-title":"Metabolically healthy obesity, transition to unhealthy metabolic status, and vascular disease in Chinese adults: a cohort study","volume":"17","author":"Gao","year":"2020","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.ejim.2023.05.012_bib0017","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-8587(18)30137-2","article-title":"Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90\u2008257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study","volume":"6","author":"Eckel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2023.05.012_bib0018","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.012_bib0019","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10160","key":"10.1016\/j.ejim.2023.05.012_bib0020","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"10295","key":"10.1016\/j.ejim.2023.05.012_bib0021","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ejim.2023.05.012_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179614","article-title":"Murine models, and clinical implications of metabolically healthy obesity","volume":"23","author":"Cho","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.012_bib0023","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1152\/physrev.00033.2011","article-title":"Pathophysiology of human visceral obesity: an update","volume":"93","author":"Tchernof","year":"2013","journal-title":"Physiol Rev"},{"issue":"7","key":"10.1016\/j.ejim.2023.05.012_bib0024","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S2213-8587(20)30110-8","article-title":"Causes, consequences, and treatment of metabolically unhealthy fat distribution","volume":"8","author":"Stefan","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.012_bib0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.106.675355","article-title":"Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham heart study","volume":"116","author":"Fox","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.012_bib0026","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2337\/dc08-1359","article-title":"Patterns of abdominal fat distribution: the Framingham heart study","volume":"32","author":"Pou","year":"2009","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ejim.2023.05.012_bib0027","doi-asserted-by":"crossref","first-page":"E439","DOI":"10.1002\/oby.20135","article-title":"Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults","volume":"21","author":"Neeland","year":"2013","journal-title":"Obesity"},{"issue":"11","key":"10.1016\/j.ejim.2023.05.012_bib0028","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/2012.jama.11132","article-title":"Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults","volume":"308","author":"Neeland","year":"2012","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ejim.2023.05.012_bib0029","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1001\/archinte.168.15.1609","article-title":"Identification and characterization of metabolically benign obesity in humans","volume":"168","author":"Stefan","year":"2008","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.ejim.2023.05.012_bib0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s13679-020-00375-0","article-title":"Metabolically healthy obesity: criteria, epidemiology, controversies, and consequences","volume":"9","author":"Tsatsoulis","year":"2020","journal-title":"Curr Obes Rep"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.012_bib0031","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jacc.2014.09.077","article-title":"The natural course of healthy obesity over 20 years","volume":"65","author":"Bell","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.ejim.2023.05.012_bib0032","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003384","article-title":"Risk of the development of diabetes and cardiovascular disease in metabolically healthy obese people: the korean genome and epidemiology study","volume":"95","author":"Kim","year":"2016","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.012_bib0033","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00394-013-0635-2","article-title":"Determinants of the transition from a cardiometabolic normal to abnormal overweight\/obese phenotype in a Spanish population","volume":"53","author":"Schroder","year":"2014","journal-title":"Eur J Nutr"},{"issue":"9","key":"10.1016\/j.ejim.2023.05.012_bib0034","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/ijo.2015.75","article-title":"Visceral abdominal fat accumulation predicts the conversion of metabolically healthy obese subjects to an unhealthy phenotype","volume":"39","author":"Hwang","year":"2015","journal-title":"Int J Obes"},{"issue":"10","key":"10.1016\/j.ejim.2023.05.012_bib0035","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/jech-2015-206948","article-title":"The long-term prognosis of cardiovascular disease and all-cause mortality for metabolically healthy obesity: a systematic review and meta-analysis","volume":"70","author":"Zheng","year":"2016","journal-title":"J Epidemiol Community Health"},{"issue":"12","key":"10.1016\/j.ejim.2023.05.012_bib0036","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacc.2017.07.763","article-title":"Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women","volume":"70","author":"Caleyachetty","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.ejim.2023.05.012_bib0037","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.012_bib0038","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejim.2023.05.012_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.100991","article-title":"Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists","volume":"37","author":"Lucey","year":"2020","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.ejim.2023.05.012_bib0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.012_bib0041","doi-asserted-by":"crossref","first-page":"F1519","DOI":"10.1152\/ajprenal.00211.2018","article-title":"GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side","volume":"315","author":"Dieter","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"10.1016\/j.ejim.2023.05.012_bib0042","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/187152512803530379","article-title":"Incretin pharmacology: a review of the incretin effect and current incretin-based therapies","volume":"10","author":"Neumiller","year":"2012","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"20","key":"10.1016\/j.ejim.2023.05.012_bib0043","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4239\/wjd.v7.i20.572","article-title":"Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity","volume":"7","author":"Anandhakrishnan","year":"2016","journal-title":"World J Diabetes"},{"key":"10.1016\/j.ejim.2023.05.012_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170206","article-title":"Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion","volume":"125","author":"Reimann","year":"2020","journal-title":"Peptides"},{"issue":"Suppl 3","key":"10.1016\/j.ejim.2023.05.012_bib0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.012_bib0046","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJMe2109957","article-title":"Breaking new ground with incretin therapy in diabetes","volume":"385","author":"Tuttle","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.012_bib0047","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ejim.2023.05.012_bib0048","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/dom.14174","article-title":"The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes","volume":"22","author":"Wilson","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.012_bib0049","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.012_bib0050","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the surpass-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"10300","key":"10.1016\/j.ejim.2023.05.012_bib0051","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"10313","key":"10.1016\/j.ejim.2023.05.012_bib0052","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejim.2023.05.012_bib0053","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/clinem\/dgab722","article-title":"Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes","volume":"107","author":"Pirro","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.012_bib0054","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ejim.2023.05.012_bib0055","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.ejim.2023.05.012_bib0056","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for eskd in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.012_bib0057","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7570\/jomes22012","article-title":"The upcoming weekly tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?","volume":"31","author":"Jung","year":"2022","journal-title":"J Obes Metab Syndr"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:39:25Z","timestamp":1760607565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523001644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":57,"alternative-id":["S0953620523001644"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.05.012","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tirzepatide and potential use for metabolically healthy obesity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}